On November 28, 2018, AgeX’s former parent company, BioTime, Inc. (NYSE American: BTX) distributed approximately 12.7 million shares of AgeX common stock to BioTime shareholders in the ratio of one share of AgeX common stock for every 10 BioTime common shares owned. There are approximately 35.8 million shares of AgeX common stock outstanding of which approximately 1.7 million are held by BioTime
BioTime received $43M from Juvenescence for 14.4M shares of AgeX Therapeutics in August, 2018
Additional information about AgeX, its core technologies including its proprietary PureStem® and induced Tissue Regeneration AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology.
Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which AgeX plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, AgeX, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. AgeX also markets Cytiva® comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.